Mostrar el registro sencillo del ítem
Association of baseline CD4+ cell count and HIV-RNA on sustained virologic response to interferon-ribavirin in HIV/HCV coinfected patients
dc.contributor.author | Aldámiz-Echevarría, Teresa | |
dc.contributor.author | González-García, Juan | |
dc.contributor.author | Von Wichmann, Miguel A. | |
dc.contributor.author | Crespo, Manel | |
dc.contributor.author | López-Aldeguer, José | |
dc.contributor.author | Quereda, Carmen | |
dc.contributor.author | Téllez, María J. | |
dc.contributor.author | Galindo, María J. | |
dc.contributor.author | Sanz, José | |
dc.contributor.author | Santos, Ignacio | |
dc.contributor.author | Guardiola Tey, Josep Maria | |
dc.contributor.author | Bellón, José M. | |
dc.contributor.author | Montes, Marisa | |
dc.contributor.author | Berenguer, Juan | |
dc.contributor.author | GESIDA HIV-HCV Cohort Study Group | |
dc.date.accessioned | 2021-06-17T17:16:54Z | |
dc.date.available | 2021-06-17T17:16:54Z | |
dc.date.issued | 2015 | |
dc.identifier.citation | Aldámiz-Echevarría, Teresa; González-García, Juan; Von Wichmann, Miguel A. [et al.]. Association of baseline CD4+ cell count and HIV-RNA on sustained virologic response to interferon-ribavirin in HIV/HCV coinfected patients. Annals of Hepatology, 2015, 14(4), p. 464-469. Disponible en: <https://www.sciencedirect.com/science/article/pii/S1665268119311676?via%3Dihub>. Fecha de acceso: 17 jun. 2021. DOI: 10.1016/S1665-2681(19)31167-6 | ca |
dc.identifier.issn | 1665-2681 | ca |
dc.identifier.uri | http://hdl.handle.net/20.500.12328/2638 | |
dc.description.abstract | Background and rationale for the study. We assessed the association of CD4+ T-cell counts and HIV-RNA onsustained viral response (SVR) after therapy with pegylated interferon and ribavirin (PR) in HIV/HCV coin-fected patients. We examined two large cohorts of coinfected patients treated with PR in Spain between2000 and 2008. SVR was defined as undetectable HCV-RNA at 24 weeks after the end of PR. Results.Westudied 1682 patients, of whom 38% achieved SVR. Baseline factors independently associated with reducedodds of SVR included genotype 1 or 4, HCV-RNA > 500,000 IU/mL, advanced liver fibrosis, CDC clinical cate-gory C, and detectable HIV-RNA. By multivariate logistic regression analysis, we found that, in comparisonwith patients with combination antiretroviral therapy (cART) and undetectable HIV-RNA, the odds ratio[95% confidence interval (CI)] of SVR was 0.56 (0.41-0.78) for cART and detectable HIV-RNA, 0.86 (0.56-2.57)for no-cART and detectable HIV-RNA, and 1.38 (0.74-2.57) for no-cART and undetectable HIV-RNA. Conclu-sions.Detectable HIV-RNA, but not CD4+ T-cell count, was associated with reduced odds of SVR. However,this finding was only confirmed for cART and detectable HIV-RNA, raising the question as whether this rep-resents a true association of HIV-RNA on response to PR or a spurious association due to poor adherenceto treatment. | en |
dc.format.extent | 6 | ca |
dc.language.iso | eng | ca |
dc.publisher | Elsevier | ca |
dc.relation.ispartof | Annals of Hepatology | ca |
dc.relation.ispartofseries | 14;4 | |
dc.rights | Under a Creative Commons license | en |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/4.0/ | |
dc.subject.other | Hepatitis C | ca |
dc.subject.other | Virus de la immunodeficiència humana | ca |
dc.subject.other | Interferó pegilat | ca |
dc.subject.other | Resposta viral sostinguda | ca |
dc.subject.other | Hepatitis C crònica | es |
dc.subject.other | Hepatitis C | es |
dc.subject.other | Virus de la inmunodeficiencia humana | es |
dc.subject.other | Interferón pegilado | es |
dc.subject.other | Respuesta viral sostenida | es |
dc.subject.other | Hepatitis C crónica | es |
dc.subject.other | Hepatitis C | en |
dc.subject.other | Human immunodeficiency virus | en |
dc.subject.other | Pegilat interfered | en |
dc.subject.other | Sustained viral response | en |
dc.subject.other | Chronic hepatitis C | en |
dc.title | Association of baseline CD4+ cell count and HIV-RNA on sustained virologic response to interferon-ribavirin in HIV/HCV coinfected patients | en |
dc.type | info:eu-repo/semantics/article | ca |
dc.description.version | info:eu-repo/semantics/publishedVersion | ca |
dc.rights.accessLevel | info:eu-repo/semantics/openAccess | |
dc.embargo.terms | cap | ca |
dc.subject.udc | 61 | ca |
dc.subject.udc | 616.9 | ca |
dc.identifier.doi | https://dx.doi.org/10.1016/S1665-2681(19)31167-6 | ca |
Ficheros en el ítem
Este ítem aparece en la(s) siguiente(s) colección(ones)
-
Ciències de la Salut [738]